References
- Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Global lung initiative for chronic obstructive lung disease (GOLD) 2020 report. Available from: https://goldcopd.org/wp-content/uploads/2019/GOLD-2020-REPORT-ver1.0wms.pdf
- Lamprecht B, Soriano JB, Studnicka M, et al. Determinants of underdiagnosis of COPD in National and International Surveys. Chest 2015;148(4):971–985. doi:10.1378/chest.14-2535.
- Belgrave DCM, Granell R, Turner SW, et al. Lung function trajectories from pre-school age to adulthood and their associations with early life factors: a retrospective analysis of three population-based birth cohort studies. Lancet Respir Med. 2018;6(7):526–534. doi:10.1016/S2213-2600(18)30099-7.
- Bui DS, Lodge CJ, Burgess JA, et al. Childhood predictors of lung function trajectories and future COPD risk: a prospective cohort study from the first to the sixth decade of life. Lancet Respir Med. 2018;6(7):535–544. doi:10.1016/S2213-2600(18)30100-0.
- Institute for Health Metrics and Evaluation (IHME). GBD compare data visualization. Seattle, WA: University of Washington; 2017. https://vizhub.healthdata.org/gbd-compare/
- Bhatt SP, Balte PP, Schwartz JE, et al. Discriminative accuracy of FEV1: FVC thresholds for COPD-related hospitalization and mortality. JAMA 2019;321(24):2438–2447. doi:10.1001/jama.2019.7233.
- Boppana LKT, Sakhamuri S, Seemungal T. Spirometric instability – another hurdle in achieving real-world COPD diagnostic criteria? COPD 2018;15(6):557–558. doi:10.1080/15412555.2018.1534947.
- O'Donnell DE, Elbehairy AF, Webb KA, et al. Canadian respiratory research network. The link between reduced inspiratory capacity and exercise intolerance in chronic obstructive pulmonary disease. Annals ATS. 2017;14(Supplement_1):S30–S39. doi:10.1513/AnnalsATS.201610-834FR.
- Balasubramanian A, MacIntyre NR, Henderson RJ, et al. Diffusing capacity of carbon monoxide in assessment of COPD. Chest 2019;156(6):1111–1119. doi:10.1016/j.chest.2019.06.035.
- Arjomandi M, Zeng S, Barjaktarevic I, et al. SPIROMICS investigators. Radiographic lung volumes predict progression to COPD in smokers with preserved spirometry in SPIROMICS. Eur Respir J. 2019;54(4):1802214. doi:10.1183/13993003.02214-2018.
- Vestbo J, Lange P. Can GOLD Stage 0 provide information of prognostic value in chronic obstructive pulmonary disease? Am J Respir Crit Care Med. 2002;166(3):329–332. doi:10.1164/rccm.2112048.
- Hastie AT, Martinez FJ, Curtis JL, et al. SPIROMICS investigators. Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort. Lancet Respir Med. 2017;5(12):956–967. doi:10.1016/S2213-2600(17)30432-0.
- Tashkin DP, Pearle J, Iezzoni D, et al. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD 2009;6(1):17–25. doi:10.1080/15412550902724073.
- Mahler DA, Decramer M, D'Urzo A, et al. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study. Eur Respir J. 2014;43(6):1599–1609. doi:10.1183/09031936.00124013.
- Singh D, Ferguson GT, Bolitschek J, et al. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. Respir Med. 2015;109(10):1312–1319. doi:10.1016/j.rmed.2015.08.002.
- Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012;(9):CD006829.
- Vestbo J, Leather D, Diar Bakerly N, et al. Effectiveness of fluticasone furoate-vilanterol for COPD in clinical practice. N Engl J Med. 2016;375(13):1253–1260. doi:10.1056/NEJMoa1608033.